Absci (NASDAQ:ABSI) Stock Rating Reaffirmed as “Buy” by BTIG Research

Absci (NASDAQ:ABSI)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a note issued to investors on Thursday, Benzinga reports. They presently have a $16.00 price objective on the stock. BTIG Research‘s price objective would indicate a potential upside of 75.05% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating on shares of Absci in a research report on Tuesday, October 20th. Wall Street Zen upgraded Absci from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. upped their price objective on shares of Absci from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Thursday, October 15th. Finally, Jefferies Financial Group began coverage on shares of Absci in a research note on Thursday, October 29th. They set a “buy” rating and a $14.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Absci has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Absci Trading Down 9.7%

ABSI stock opened at $9.14 on Thursday. Absci has a twelve month low of $2.24 and a twelve month high of $12.54. The company’s 50 day moving average is $9.66 and its two-hundred day moving average is $6.78. The stock has a market cap of $1.57 billion, a P/E ratio of -11.43 and a beta of 2.22.

Absci (NASDAQ:ABSI) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. On average, equities research analysts predict that Absci will post -0.76 earnings per share for the current year.

Hedge Funds Weigh In On Absci

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Absci during the second quarter worth $141,112,000. Siren L.L.C. acquired a new stake in Absci in the first quarter valued at $5,400,000. Parkman Healthcare Partners LLC purchased a new position in shares of Absci in the second quarter valued at $10,366,000. Bank of America Corp DE purchased a new position in shares of Absci in the second quarter valued at $6,560,000. Finally, Artia Global Partners LP purchased a new position in shares of Absci in the second quarter valued at $5,383,000. 52.05% of the stock is owned by institutional investors and hedge funds.

Key Absci News

Here’s some of the latest news about ABSI:

• Positive Sentiment: Absci said its ABS-201 HEADLINE trial for pattern hair loss remains on track, with 13-week interim proof-of-concept data expected in December 2026 and full 26-week results anticipated in early 2027. Those results are a key near-term catalyst. Article: Absci Q3 2026: December hair-loss data is the only number that matters
• Positive Sentiment: The company had $173.7 million in cash, cash equivalents and marketable securities at quarter-end, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Article: Absci Reports Third-Quarter Results
• Negative Sentiment: Quarterly revenue was $0.3 million, below the cited $0.66 million consensus estimate, while net loss widened to $33.3 million from $28.7 million a year earlier. The reported $0.19 loss per share met one consensus estimate, although another source said it missed its estimate—adding to the mixed earnings read-through. Article: Absci Reports Q3 Loss, Misses Revenue Estimates

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.